Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article

Khalifa, Alaa M.; Elsheikh, Manal A; Khalifa, A.; Elnaggar, Yosra S.R.

doi:10.1016/j.jconrel.2019.08.034

Cited by 70 publications

(47 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Paclitaxel (PTX) is one of the most common chemotherapy drugs used for OC treatment. 13 A recent study indicated that circCELSR1 could promote the PTX resistance of OC in mediating the miR-1252/FOXR2 axis. 14 Therefore, circRNA is also expected to be a potential target for overcoming cancer resistance.…”

Section: Introductionmentioning

confidence: 99%

<p>Downregulation of circNRIP1 Suppresses the Paclitaxel Resistance of Ovarian Cancer via Regulating the miR-211-5p/HOXC8 Axis</p>

Cai

Han

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Circular RNA (circRNA) has an essential regulatory role in the chemotherapy resistance of cancers. Nevertheless, the role of circRNA nuclear receptor-interacting protein 1 (circNRIP1) in the paclitaxel (PTX) resistance of ovarian cancer (OC) remains unclear. Material and Methods: The circNRIP1, miR-211-5p and homeobox C8 (HOXC8) expression levels were assessed using qRT-PCR. The PTX resistance of cells was measured by 3-(4, 5-dimethylthiazolyl-2-yl)-2-5 diphenyl tetrazolium bromide (MTT) assay. Furthermore, cell proliferation, apoptosis, migration and invasion were detected by colony formation assay, flow cytometry and transwell assay, respectively. Moreover, the protein levels of proliferation, apoptosis, metastasis-related markers and HOXC8 were determined by Western blot (WB) analysis. Tumor xenograft models were constructed to explore the influence of circNRIP1 on OC tumor growth. The interaction between miR-211-5p and circNRIP1 or HOXC8 was confirmed by dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Results: CircNRIP1 was highly expressed in PTX-resistant OC tissues and cells. Silencing of circNRIP1 repressed the PTX resistance of OC cells in vitro and OC tumor in vivo. Furthermore, circNRIP1 sponged miR-211-5p, and miR-211-5p inhibitor could reverse the inhibitory effect of circNRIP1 knockdown on the PTX resistance of OC cells. In addition, miR-211-5p targeted HOXC8, and HOXC8 overexpression could reverse the suppression effect of miR-211-5p on the PTX resistance of OC cells. Additionally, the expression of HOXC8 was regulated by circNRIP1 and miR-211-5p. Conclusion: CircNRIP1 silencing could inhibit the PTX resistance of OC via regulating the miR-211-5p/HOXC8 axis, showing that circNRIP1 might be a potential target for OC resistance treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Downregulation of circNRIP1 Suppresses the Paclitaxel Resistance of Ovarian Cancer via Regulating the miR-211-5p/HOXC8 Axis</p>

Cai

Han

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Its chemotherapeutic effect is associated with its ability to bind to tubulin promoting microtubule assembly, stabilizing the existing microtubules and enhancing the action of tubulin dimers, therefore inhibiting their disassembly. This interferes with the late G2 mitotic phase of the cell cycle, and inhibits cellular replication suppressing the metastasis of cancer cells [ 7 , 8 ]. In addition, PTX may stimulate tumor necrosis factors, inhibit tumor-angiogenesis and induce cytokines and tumor-suppressor genes [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

“…In addition, PTX may stimulate tumor necrosis factors, inhibit tumor-angiogenesis and induce cytokines and tumor-suppressor genes [ 8 , 9 ]. PTX has shown remarkable antitumor properties, especially in the treatment of lung, ovarian and breast cancers, with moderate efficacy on HNSCC [ 7 , 10 , 11 , 12 ]. Its poor water solubility, inadequate selectivity and significant systemic side effect have limited its intravenous (IV) administration for the treatment of HNSCC [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

“…The use of polymeric NPs as carriers for lipophilic drugs, including PTX, has significantly increased the therapeutic effect of those drugs, by improving their aqueous solubility, altering their biodistribution profile, and protecting them against enzymatic degradation [ 7 , 20 ]. NPs smaller than 100 nm can also passively target the tumor via enhanced permeability retention (EPR) effect, where appropriately sized particles extravasate through the tumor vasculature and accumulate locally, which sustains the drug concentration compared to the parent small molecule [ 16 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Optimization and Evaluation of Poly(lactide-co-glycolide) Nanoparticles for Enhanced Cellular Uptake and Efficacy of Paclitaxel in the Treatment of Head and Neck Cancer

et al. 2020

View full text Add to dashboard Cite

The particle size (PS) and encapsulation efficiency (EE%) of drug-loaded nanoparticles (NPs) may inhibit their cellular uptake and lead to possible leakage of the drug into the systemic circulation at the tumor site. In this work, ultra-high paclitaxel-loaded poly(lactide-co-glycolide) NPs (PTX-PLGA-NPs) with ultra-small sizes were prepared and optimized by adopting the principles of quality by design (QbD) approach. The optimized PTX-PLGA-NPs showed ultra-small spherical particles of about 53 nm with EE% exceeding 90%, a relatively low polydispersity index (PDI) of 0.221, an effective surface charge of −10.1 mV, and a 10-fold increase in the in vitro drug release over 72 h relative to free drug. The cellular viability of pharynx carcinoma cells decreased by almost 50% in 24 h following treatment with optimized PTX-PLGA-NPs, compared to only 20% from the free drug. The intracellular uptake of PTX-PLGA-NPs was highly favored, and the antitumor activity of PTX was remarkably improved with a reduction in its half maximal inhibitory concentration (IC50), by almost 50% relative to free drug solution. These results suggest that the optimal critical formulation parameters, guided by QbD principles, could produce PLGA-NPs with remarkably high EE% and ultra-small PS, resulting in enhanced cellular uptake and efficacy of PTX.

show abstract

“…However, repeated large‐volume administrations of oil‐based formulations can lead to muscle granuloma, fibrosis and accumulation of oil (Hay, 1995). Additionally, a wealth of data has indicated that castor oil as a co‐solvent can lead to important adverse effects, including acute hypersensitivity reactions (Khalifa, Elsheikh, Khalifa, & Elnaggar, 2019; ten Tije, Verweij, Loos, & Sparreboom, 2003; Weiss et al, 1990). Wang, Dan, & Liang (2010) attempted to develop aqueous microspheres for an injection containing fulvestrant based on Polylactic acid‐polyethylene glycol ended monomethyl ether (PLA‐MPEG) to eliminate adverse reactions associated with castor oil.…”

Section: Introductionmentioning

confidence: 99%

Liquid chromatography tandem mass spectrometry method for determination of fulvestrant in rat plasma and its application to pharmacokinetic studies of a novel fulvestrant microcrystal

Leng

Zuo

et al. 2020

Biomedical Chromatography

View full text Add to dashboard Cite

Fulvestrant (‘Faslodex’), an estrogen receptor antagonist, is available for the treatment of advanced breast cancer. The oil‐based vehicle of Faslodex can lead to various adverse effects. A novel fulvestrant microcrystal (aqueous suspension) was developed in this study to eliminate these adverse effects. A sensitive and robust liquid chromatography tandem mass spectrometry method was developed and validated for the determination of fulvestrant in rat plasma using supported‐liquid extraction. The separation of fulvestrant was achieved on an Agilent SB‐C18 column (2.1 × 50 mm, 3.5 μm) with isocratic elution using fulvestrant‐d3 as internal standard. Mass spectrometric detection was conducted in negative multiple reaction monitoring mode. Ion transitions were at m/z 605.5 → 427.5 for fulvestrant and m/z 608.5 → 430.5 for fulvestrant‐d3. The excellent linearity was demonstrated over the range 0.05–100.0 ng/ml (r2 = 0.99). The lower limit of quantitation was 0.05 ng/ml, which was superior to that reported in literature The method validation was evaluated by selectivity, accuracy, precision, recovery and matrix effect in agreement with the US Food and Drug Administration guidance. The method was successfully applied to a pharmacokinetic study of a novel fulvestrant microcrystal in rats after intramuscular administration. It revealed that the rate of absorption increases and the extent of absorption is constant with a decrease in microcrystal diameter.

show abstract

Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article

Cited by 70 publications

References 153 publications

<p>Downregulation of circNRIP1 Suppresses the Paclitaxel Resistance of Ovarian Cancer via Regulating the miR-211-5p/HOXC8 Axis</p>

<p>Downregulation of circNRIP1 Suppresses the Paclitaxel Resistance of Ovarian Cancer via Regulating the miR-211-5p/HOXC8 Axis</p>

Optimization and Evaluation of Poly(lactide-co-glycolide) Nanoparticles for Enhanced Cellular Uptake and Efficacy of Paclitaxel in the Treatment of Head and Neck Cancer

Liquid chromatography tandem mass spectrometry method for determination of fulvestrant in rat plasma and its application to pharmacokinetic studies of a novel fulvestrant microcrystal

Contact Info

Product

Resources

About